Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.

The benefits of recombinant human erythropoietin (rHuEPO) administration in dialysis patients have been demonstrated, however the optimal frequency regimen have yet to be established.